Draft guideline on the clinical development of medicinal products for the treatment of human-immunodeficiency-virus (HIV) infection (revision 3)

  • Email
  • Help

Document details

Download document Draft guideline on the clinical development of medicinal products for the treatment of human-immunodeficiency-virus (HIV) infection (revision 3)
Reference number EMEA/CPMP/EWP/633/02 Rev. 3
Status draft: consultation closed
First published 2013-09-30
Last updated 2013-10-07

Summary

This guideline provides guidance on the clinical development of direct-acting antiretrovirals for the treatment of human-immunodeficiency-virus (HIV) infection. It replaces EMEA/CPMP/EWP/633/02 Rev 2.